AR049177A1 - Polipeptidos y conjugados de interferon-alfa - Google Patents

Polipeptidos y conjugados de interferon-alfa

Info

Publication number
AR049177A1
AR049177A1 ARP050102059A ARP050102059A AR049177A1 AR 049177 A1 AR049177 A1 AR 049177A1 AR P050102059 A ARP050102059 A AR P050102059A AR P050102059 A ARP050102059 A AR P050102059A AR 049177 A1 AR049177 A1 AR 049177A1
Authority
AR
Argentina
Prior art keywords
polypeptides
conjugates
nucleic acids
interferon
alfa
Prior art date
Application number
ARP050102059A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Maxygen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche, Maxygen Inc filed Critical Hoffmann La Roche
Publication of AR049177A1 publication Critical patent/AR049177A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Polipéptidos y conjugados de interferon-alfa, y ácidos nucleicos que codifican los polipéptidos. También se incluyen composiciones que comprenden estos polipéptidos, conjugados y ácidos nucleicos; células que contienen o expresan los polipéptidos, los conjugados y los ácidos nucleicos; métodos para preparar los polipéptidos, los conjugados y los ácidos nucleicos; y métodos para usar los polipéptidos, los conjugados y los ácidos nucleicos. Reivindicacion 1: Un polipéptido aislado o recombinante caracterizado porque comprende una secuencia que (a) difiere en entre 1 y 16 posiciones de aminoácidos de SEQ ID No. 1, y (b) comprende una o más sustituciones respecto de SEQ ID No. 1 seleccionadas del grupo que consiste en F48A/L; V51P; F55A; F65A; F68P; L111A; y V114P; donde el polipéptido presenta actividad antiviral.
ARP050102059A 2004-05-19 2005-05-19 Polipeptidos y conjugados de interferon-alfa AR049177A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US57250404P 2004-05-19 2004-05-19

Publications (1)

Publication Number Publication Date
AR049177A1 true AR049177A1 (es) 2006-07-05

Family

ID=35428915

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050102059A AR049177A1 (es) 2004-05-19 2005-05-19 Polipeptidos y conjugados de interferon-alfa

Country Status (14)

Country Link
US (9) US7318918B2 (es)
EP (1) EP1753779A2 (es)
JP (1) JP2008507298A (es)
CN (1) CN101115769A (es)
AR (1) AR049177A1 (es)
AU (1) AU2005245918A1 (es)
BR (1) BRPI0511196A (es)
CA (1) CA2566247A1 (es)
IL (1) IL178470A0 (es)
MX (1) MXPA06013412A (es)
NO (1) NO20065084L (es)
RU (1) RU2006145020A (es)
TW (1) TW200611910A (es)
WO (1) WO2005113592A2 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040005673A1 (en) * 2001-06-29 2004-01-08 Kevin Jarrell System for manipulating nucleic acids
DE60042730D1 (de) 1999-01-05 2009-09-24 Univ Boston Verbessertes klonierungsverfahren
US7435562B2 (en) 2000-07-21 2008-10-14 Modular Genetics, Inc. Modular vector systems
US20030017552A1 (en) * 2000-07-21 2003-01-23 Jarrell Kevin A. Modular vector systems
EP1759521B1 (en) * 2004-05-12 2016-06-29 Synchronoss Technologies, Inc. Advanced contact identification system
JP2008519602A (ja) * 2004-11-11 2008-06-12 モジュラー ジェネティクス， インコーポレイテッド 多様性を生じるためのラダーアセンブリおよびシステム
EP2537527A3 (en) * 2005-03-09 2013-02-20 Guangwen Wei Uses of recombinant super-compound interferons
MX2007014524A (es) 2005-05-18 2008-02-07 Maxygen Inc Polipeptidos desarrollados de interferon-alfa.
AR078117A1 (es) * 2006-06-20 2011-10-19 Protech Pharma S A Una muteina recombinante del interferon alfa humano glicosilado, un gen que codifica para dicha muteina, un metodo de produccion de dicho gen, un metodo para obtener una celula eucariota productora de dicha muteina, un metodo para producir dicha muteina, un procedimiento para purificar dicha muteina
WO2008008808A2 (en) * 2006-07-11 2008-01-17 Modular Genetics Inc. Methods of introducing targeted diversity into nucleic acid molecules
EP2042513A4 (en) * 2006-07-25 2010-07-07 Galpharma Co Ltd Galectin-9-POLYMER CONJUGATE
US7808342B2 (en) * 2006-10-02 2010-10-05 Skyworks Solutions, Inc. Harmonic phase tuning filter for RF switches
WO2008124086A2 (en) 2007-04-05 2008-10-16 President And Fellows Of Harvard College Chimeric activators: quantitatively designed protein therapeutics and uses thereof
US7625555B2 (en) 2007-06-18 2009-12-01 Novagen Holding Corporation Recombinant human interferon-like proteins
WO2009006579A1 (en) * 2007-07-05 2009-01-08 Pharmaessentia Corp. Peptide-polymer conjugates
AU2008308805B2 (en) * 2007-10-01 2013-05-30 Pharmaessentia Corp. N-terminal modified interferon-alpha
WO2009090056A2 (en) * 2008-01-18 2009-07-23 F. Hoffmann-La Roche Ag Purification of not-glycosylated polypeptides
US7954022B2 (en) * 2008-01-30 2011-05-31 Alcatel-Lucent Usa Inc. Apparatus and method for controlling dynamic modification of a scan path
EP2358395A4 (en) * 2008-11-17 2013-11-20 Hoffmann La Roche METHOD AND FORMULATION FOR REDUCING THE AGGREGATION OF A MACROMOLECULUM UNDER PHYSIOLOGICAL CONDITIONS
US8940501B2 (en) 2009-01-30 2015-01-27 Whitehead Institute For Biomedical Research Methods for ligation and uses thereof
AR086659A1 (es) * 2011-06-02 2014-01-15 Hanmi Science Co Ltd Multimero de insulina-polimero no peptidilo y metodo para su produccion
JP2014525904A (ja) 2011-06-28 2014-10-02 ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ タンパク質連結用クリックケミストリーハンドルを設置するためのソルターゼの使用
CN102358897B (zh) * 2011-10-31 2013-02-13 北京三元基因工程有限公司 重组人寡腺苷酸合成酶-1的制备方法
WO2015168474A1 (en) 2014-04-30 2015-11-05 President And Fellows Of Harvard College Fusion proteins for treating cancer and related methods
DK3006045T3 (en) * 2014-10-07 2017-07-17 Cyprumed Gmbh Pharmaceutical formulations for oral administration of peptide or protein drugs
US10525137B2 (en) 2015-12-30 2020-01-07 Genentech, Inc. Formulations with reduced degradation of polysorbate
RU2650755C1 (ru) * 2017-05-24 2018-04-17 Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства России (ФГБУ "ГНЦ Институт иммунологии" ФМБА России) Способ очистки лекарственного средства пролонгированного действия на основе рекомбинантного аналога интерферона альфа-17 для лечения вирусного гепатита С
BR112022014567A2 (pt) * 2020-01-24 2022-09-27 Alkermes Pharma Ireland Ltd Métodos de purificação

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610830B1 (en) 1980-07-01 2003-08-26 Hoffman-La Roche Inc. Microbial production of mature human leukocyte interferons
ES8302778A1 (es) 1980-11-10 1983-02-01 Genentech Inc Un procedimiento para producir un polipeptido antiviral.
US4414150A (en) 1980-11-10 1983-11-08 Genentech, Inc. Hybrid human leukocyte interferons
WO1983002461A1 (en) 1982-01-19 1983-07-21 Cetus Corp Multiclass hybrid interferons
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
JPS60152058A (ja) * 1984-01-20 1985-08-10 Toshiba Corp 半導体記憶装置
EP0205404B1 (en) 1985-06-11 1992-07-15 Ciba-Geigy Ag Hybrid interferons
US4695626A (en) * 1986-07-29 1987-09-22 Pfizer Inc. 1-aza-4,5-dithiabicyclo [4.2.0] oct-2-en-8-one-2 carboxylate esters
US5372808A (en) 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
AU660633B2 (en) 1990-10-17 1995-07-06 Amgen, Inc. Methods and compositions for the treatment of cell proliferation disorders
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5574138A (en) 1993-03-08 1996-11-12 Immunex Corporation Epithelium-derived T-cell factor
US6335160B1 (en) 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
ES2186714T3 (es) 1994-03-07 2003-05-16 Imperial College Uso de sustipo simple alpha 8 en la preparacion de medicamentos para el tratamiento de infecciones virales del higado.
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
CN1269805A (zh) 1997-07-14 2000-10-11 博尔德生物技术公司 生长激素和相关蛋白的衍生物
NZ513077A (en) 1999-01-14 2004-03-26 Bolder Biotechnology Inc Methods for making proteins containing free cysteine residues
AU3725600A (en) * 1999-03-02 2000-09-21 Maxygen, Inc. Surrogate orphan ligands for orphan receptors
CA2372400C (en) 1999-05-19 2010-04-27 Lexigen Pharmaceuticals Corp. Expression and export of interferon-alpha proteins as fc fusion proteins
US20040002474A1 (en) 1999-10-07 2004-01-01 Maxygen Inc. IFN-alpha homologues
JP2003511031A (ja) * 1999-10-07 2003-03-25 マキシジェン， インコーポレイテッド ＩＦＮ−αホモログ
CA2390292A1 (en) * 1999-11-12 2001-05-25 Maxygen Holdings Ltd. Interferon gamma conjugates
AU7485301A (en) 2000-05-16 2001-11-26 Bolder Biotechnology Inc Methods for refolding proteins containing free cysteine residues
AU2002223350A1 (en) 2000-12-01 2002-06-11 Eleanor N. Fish Cytokine receptor binding peptides
KR100459105B1 (ko) 2001-02-15 2004-12-03 선바이오(주) 변형된 인터페론-알파 2ａ 및 2ｂ, 그리고 이들과 ＰＥＧ유도체와의 배합체
PL376883A1 (pl) 2002-11-15 2006-01-09 F. Hoffmann-La Roche Ag Izomery podstawienia PEG IFN alfa 2a
EP1565205A4 (en) 2002-11-18 2006-07-05 Maxygen Inc INTERFERON-ALPHA POLYPEPTIDES AND CONJUGATES

Also Published As

Publication number Publication date
US7537755B2 (en) 2009-05-26
CN101115769A (zh) 2008-01-30
US20070020235A1 (en) 2007-01-25
US7541163B2 (en) 2009-06-02
CA2566247A1 (en) 2005-12-01
US20080171363A1 (en) 2008-07-17
US7531630B2 (en) 2009-05-12
US7318918B2 (en) 2008-01-15
NO20065084L (no) 2006-12-01
WO2005113592A2 (en) 2005-12-01
BRPI0511196A (pt) 2007-12-04
RU2006145020A (ru) 2008-06-27
EP1753779A2 (en) 2007-02-21
US20070020734A1 (en) 2007-01-25
US20070025966A1 (en) 2007-02-01
IL178470A0 (en) 2007-02-11
US20080031853A1 (en) 2008-02-07
US7531324B2 (en) 2009-05-12
MXPA06013412A (es) 2007-01-23
US20070225204A1 (en) 2007-09-27
AU2005245918A1 (en) 2005-12-01
JP2008507298A (ja) 2008-03-13
WO2005113592A3 (en) 2006-04-06
US20050266465A1 (en) 2005-12-01
US20080076710A1 (en) 2008-03-27
US7541436B2 (en) 2009-06-02
TW200611910A (en) 2006-04-16
US20070225205A1 (en) 2007-09-27

Similar Documents

Publication Publication Date Title
AR049177A1 (es) Polipeptidos y conjugados de interferon-alfa
ES2545457T3 (es) Vacunas de péptidos para cánceres que expresan los polipéptidos DEPDC1
ATE400656T1 (de) Mini-dystrophin nukleinsäure- und peptidsequenzen
ES2513716T3 (es) Enzimas lecitina-colesteros acitransferasa modificadas
DK2014678T3 (da) KDR-peptider og vacciner indeholdende disse
ES2507094T3 (es) Proteína específica del timo
HK1205193A1 (en) Recombinant n-glycosylated proteins from procaryotic cells n-
ES2536974T3 (es) Péptidos de epítopos del receptor de EGF y usos de los mismos
ES2531142T3 (es) Péptidos WT1 de unión a HLA de clase II, y composiciones y métodos que los comprenden
EP2573109A3 (en) Peptide vaccines comprising Seq Id 101, 80 or 100 for cancers expressing tumor-associated antigens
CO5700788A2 (es) Composiciones y metodos para inmunoterapia especifica de wt1
MXPA02006888A (es) Flavivirus recombinantes y metodos para utilizar los mismos.
MX2010004371A (es) Proteasa de streptomyces.
NO20052363L (no) Interferon-alfa polypeptider og konjugater
ES2531290T3 (es) Transferasas y oxidorreductasas, ácidos nucleicos que las codifican y métodos para prepararlas y usarlas
CO6251278A2 (es) Metodo para la produccion de conjugados del factor de crecimiento similar a la insulina -1 y polietilenglicol
NZ580378A (en) Recombinant expression vector elements (reves) for enhancing expression of recombinant proteins in host cells
AR059300A1 (es) Peptidos inhibidores de la fusion de vih con propiedades biologicas mejoradas
AR067980A1 (es) Peptidos de cdh3 y agentes que los comprenden
AR070491A1 (es) Variante de enzima lipolitica con estabilidad aumentada y polinucleotidos que la codifican
AR042968A1 (es) Anticuerpos de virus anti-dengue composiciones metodos y usos
AR087719A2 (es) Celula de planta transformada, cultivo de tejidos y planta transgenica
DK1962889T3 (da) Immunogent polypeptid nestående af tumorantigenafledte optimerede kryptiske peptider samt anvendelser deraf
DK1276763T3 (da) Anti-fryseproteiner, deres fremstilling og anvendelse
AR061393A1 (es) Componentes transportadores de nitrato

Legal Events

Date Code Title Description
FB Suspension of granting procedure